BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Avistone Biotechnology readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Avistone Biotechnology's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07336732-2208@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Andamertinib: Phase 2 readout est. (NCT07336732)
DESCRIPTION:Andamertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: An
 damertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-d
 oublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutatio
 ns\nEstimated primary completion: November 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/andamertinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07336732
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06343064-2208@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Andamertinib: Phase 1/2 readout est. (NCT06343064)
DESCRIPTION:Andamertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Vebreltinib Plus PLB1004 in EGFR-mutated\, Advanced NSCLC With MET Amplifi
 cation or MET Overexpression Following EGFR-TKI\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/andamertinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06343064
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970782-2208@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Andamertinib: Phase 3 readout est. (NCT06970782)
DESCRIPTION:Andamertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ve
 breltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patie
 nts With EGFRm\, MET+\, Locally Advanced or Metastatic NSCLC Following EGF
 R-TKI Failure\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/andamertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06970782
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06281964-2208@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Andamertinib: Phase 3 readout est. (NCT06281964)
DESCRIPTION:Andamertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ef
 ficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCL
 C Harboring EGFR Exon 20 Insertion.\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/andamertinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06281
 964
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07538804-2347@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:ANS02: Phase 1/2 readout est. (NCT07538804)
DESCRIPTION:ANS02\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Smal
 l Cell Lung Cancer\nEstimated primary completion: 30 June 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ans02#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07538804
URL:https://assetmemo.bio/drug/ans02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
